CERENOVUS Launches Next Generation Catheter to Treat Acute Ischemic Stroke in Europe


Next-generation aspiration catheter – CEREGLIDE™ 71 Aspiration Catheter with TruCourse™ technology – now available across Europe

Optimized for effective direct aspiration and delivery of compatible stent retrievers, including the EMBOTRAP™ III Revascularization Device, into the neurovasculature

Latest innovation to join the CERENOVUS Stroke Solutions portfolio which is developed by using the company’s expert stroke science insights from its Neuro Thromboembolic Initiative (NTI)

Irvine, CA – April 16, 2024 – CERENOVUS, Inc., part of Johnson & Johnson MedTech, Inc., today announced the launch of CEREGLIDE 71 Aspiration Catheter in Europe, a next-generation aspiration catheter equipped with TruCourse™ technology, indicated for the revascularization of patients suffering from acute ischemic stroke. CEREGLIDE 71 Aspiration Catheter is the latest innovation in a planned CEREGLIDE Family of Catheters to join the CERENOVUS Stroke Solutions portfolio.i CEREGLIDE 71 is optimized for effective, direct aspiration of blood clots and for the delivery of compatible stent retrievers,ii including the EMBOTRAP™ III Revascularization Device and CERENOVUS NIMBUS™ geometric clot extractor, into the neurovasculature.

“The CEREGLIDE 71 Aspiration Catheter using TruCourse™ technology represents a great advancement in acute ischemic stroke treatment,” said Mark Dickinson, Worldwide President, CERENOVUS. “It provides physicians with a greater level of flexibility while offering reliable trackabilityiii, durable delivery, and versatilityii for both direct aspiration and stent-retriever use.”

Acute ischemic strokes account for 85 percent of all strokes in Europe.1 By utilizing aspiration catheters during thrombectomy procedures, physicians can restore blood flow in the brain by directly withdrawing a blood clot or using the catheter in combination with a stent retriever. However, in up to nearly 50 percent of cases, challenging anatomical features are present that can impact access to the clot, procedure time, recanalization success, and clinical outcomes.2

The TruCourse™ technology used in the CEREGLIDE 71 Aspiration Catheter increases flexibility of the device, which is designed to deliver smoother navigation and access to clots, even in challenging anatomical conditions.iii, iv This provides physicians with optimal compatibilityv, durable delivery, and reliable trackabilityiv during thrombectomy procedures.

"The introduction of the CEREGLIDE 71 Aspiration Catheter in Europe is an important step in endovascular thrombectomy, as it allows swift targeted clot access and removal during stroke treatment,” said Professor Kyriakos Lobotesis, Imperial College London.* “With CEREGLIDE 71 Aspiration Catheter, we can now access occlusion sites and aspirate clots more rapidly and efficiently, maintaining a smooth interaction with stent retrievers when used in co-aspiration. This leads to the prompt restoration of blood flow in the patient's brain, which has the potential to save more lives and improve long-term clinical outcomes.”

Devices within the CERENOVUS Stoke Solutions portfolio are developed using CERENOVUS’ expert stroke science insights from its Neuro Thromboembolic Initiative (NTI). The results are products that have been tested in models that simulate real-world scenarios and seek to further address clinical unmet needs. The CEREGLIDE 71 Aspiration Catheter will be included in the next phase of the CERENOVUS EXCELLENT Registry, a real-world registry focused on studying stroke-inducing blood clot removal by mechanical thrombectomy.

i. CERENOVUS STROKE SOLUTIONS™ includes PROWLER Select® Plus, EMBOGUARD™, CEREBASE®, EMBOTRAP™ III and CERENOVUS NIMBUS™. EMBOGUARD™ and CEREBASE® are not compatible and should not be used together.

ii. Based on internal benchtop testing in a clinically relevant silicone flow model.

iii. More trackable than the top leading aspiration catheters available on the market based on physician evaluation in a clinically relevant silicone flow model. Lower Track forces in a clinically relevant silicone flow model compared to Zoom 71.

iv. TruCourse™ is a proprietary technology used to increase flexibility of the device.

v. Compatible with commonly sold base catheters ≥0.085" ID.

* Professor Kyriakos Lobotesis is a paid consultant to CERENOVUS. He has not been compensated for any media work.

CERENOVUS, Inc., part of Johnson & Johnson MedTech, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit CERENOVUS and connect on LinkedIn and X.

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more, visit JJMT.

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the CEREGLIDE™ 71 Aspiration Catheter and the TruCourse™ technology. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of CERENOVUS, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither CERENOVUS, Inc., nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

  1. Organisation for Economic Cooperation and Development (OECD). Health at a Glance: Europe 2020: State of Health in the EU Cycle -Mortality following stroke. Last accessed: April 2024.
  2. Penide J, et al. Systematic Review on Endovascular Access to Intracranial Arteries for Mechanical Thrombectomy in Acute Ischemic Stroke. Clin Neuroradiol 2022;32:5-12.

© CERENOVUS 2024. EM_CNV_ISCH_328094